Elken Healthcare (1789.HK): Focus on R&D+Actively Go Overseas to Start a New Journey in the Post-Harvesting Era
Elken Medical (01789.HK): Vigorously expand overseas markets with digital orthopedic technology as the lead
Elken Healthcare (01789.HK): The company's performance is in line with expectations and is optimistic about subsequent joint collection
Analysts Offer Insights on Healthcare Companies: Calliditas Therapeutics (CALT), AK Medical Holdings Ltd. (HK:1789) and Consun Pharmaceutical Group Ltd. (Frankfurt: DE:C1P)
Elken Healthcare (1789.HK): External disturbances affect performance and growth is expected to pick up in 2024
Elken Healthcare (1789.HK): Forging ahead for 23 years, optimistic about recovery+contract renewal
Elken Healthcare (1789.HK): Domestic replacement accelerates after collection of joint replacement leaders
Elken Healthcare (01789.HK): 23H1 revenue increased 22%, overseas revenue increased significantly
Research and Development | Dongfang Wealth Securities: The price-for-volume plan for Elken Healthcare after the “increase in holdings” rating collection continues to be implemented in a positive way
Elken Healthcare (01789.HK) 2023 Interim Report Review: Product Volume Remarkable, 3D Printing Technology Continues to Advance
Elken Healthcare (1789.HK): Accelerate collection, increase share, and rapidly release off-standard products
Elken Healthcare (01789.HK): 1H23 is in line with expectations, collection pressure, fresh product growth is impressive
AK MEDICAL(1789.HK):SOLID GROWTH DRIVEN BY INCREASING NON-VBP SALES
Elken Healthcare (1789.HK): Domestic joint leaders continue to advance import substitution
Elken Healthcare (1789): Growth slows down due to the base effect and is expected to accelerate in the second half of the year
Elken Healthcare (1789.HK): Collect perturbations across the Jointer faucet and start again
Elken Healthcare (01789.HK): Performance Meets Expectations, Accelerated Collection and Released+More Blossoms Outside Collection
Elken Healthcare (1789.HK): Joint National Procurement Channel Clearance Performance Increased Rapidly
Elken Healthcare (1789.HK): Annual results are in line with expectations, joint collection accelerates import substitution
Big Bank Ratings | CICC: For the first time, Elken Healthcare's “outperform the industry” rating target price is HK$10.88
No Data